What is the Purpose of this Study?
The purpose of this expanded access program (EAP), also known as “compassionate use,” is to provide access to an experimental medicine called daraxonrasib (RMC-6236) for patients who have been diagnosed with metastatic pancreatic adenocarcinoma. The EAP is in place for patients who have previously treated metastatic pancreatic adenocarcinoma, have tried available approved treatments, and do not have satisfactory treatment options or are unable to participate in a clinical trial. Care under the EAP will continue as usual and will not involve any additional medical tests or procedures beyond the patient’s usual care.
Eligibility
- * At least 18 years old and has provided informed consent.
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- * Histologically or cytologically confirmed PDAC with metastatic disease.
- * Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
Where can I participate?
- CS Cancer at Beverly Hills : Abrahm Levi
- CS Cancer at Cedars-Sinai Medical Center : Abrahm Levi
- CS Cancer at The Angeles Clinic and Research Institute : Abrahm Levi
More about this Clinical Trial
What is the full name of this clinical trial?
RMC-6236-401: Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib